Rheumatology News and Research

RSS

Rheumatology is a sub-specialty in internal medicine and pediatrics, devoted to the diagnosis and therapy of rheumatic diseases. Rheumatologists mainly deal with clinical problems involving joints, soft tissues and allied conditions of connective tissues.

Bone erosion reduced by denosumab

Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion according to results of a 227 patient Phase II trial presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

Study on B-cell depletion therapy

36% of patients with refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without needing further standard immunosuppressive agents, according to a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

17 Jun 2007

Early treatment with Infliximab and Methotrex shows benefit for rheumatoid arthritis

Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis (RA), according to data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain

17 Jun 2007

Obesity epidemic and rheumatoid arthritis

The global obesity epidemic was issued with a further health warning today ? that obesity exacerbates the quality of life of patients with rheumatoid arthritis (RA).

17 Jun 2007

Study reveals gender disparity in anti-TNF treatment for rheumatoid arthritis

Findings reported at EULAR 2007, the Annual European Congress of Rheumatology (EULAR) in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis (RA).

17 Jun 2007

Study shows improvement of rheumatoid arthritis during pregnancy

Disease activity in patients with rheumatoid arthritis (RA) is significantly reduced during pregnancy, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

17 Jun 2007

Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced the presentation of additional data that showed that the safety profile of Enbrel, (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy.

17 Jun 2007

Study on hand osteoarthritis

In just two years, patients with hand osteoarthritis (OA) experienced a significant increase in pain and functional limitations, according to new data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. Statistically significant radiological progression was also detected in 20% of subjects.

17 Jun 2007

New era of treatment for rheumatoid arthritis

Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition.

16 Jun 2007

How well do you know your child's pediatrician?

How well do you know your child's pediatrician? Is he or she board certified in pediatrics, or has he or she ever completed specialty training in the field?

1 Jun 2007

Drinking lots of coffee reduces the risk of gout for men

Coffee is a habit for more than 50 percent of Americans, who drink, on average, 2 cups per day.

28 May 2007

Complement receptor 3 sends a signal to dampen the immune system

Researchers from The Children's Hospital of Philadelphia and The University of Pennsylvania reported that complement receptor 3 (CR3), a protein found on cell surfaces, inhibits dendritic cells, the sentinels of the immune system, from setting off an alarm signal that brings on a full immune response.

16 May 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

Facts about rheumatoid arthritis and aging

For the better part of three decades, Sherrie Kossoudji has endeavored each day to manage the inflammation, chronic pain, tight joints and other types of physical strife caused by rheumatoid arthritis.

8 May 2007

Professor Marc Feldmann wins top lifetime achievement award

The academic who developed a treatment for autoimmune diseases that has helped millions of patients around the world last night received a prestigious lifetime achievement award at this year's European Inventor of the Year awards.

24 Apr 2007

Relationship between appearance and psychological distress in rheumatic diseases

Patients with rheumatic disease can experience physical deformities, especially of the hands and feet in the case of rheumatoid arthritis (RA), or skin rashes and lesions and hand deformity in the case of systemic lupus erthyematosus.

28 Feb 2007

Influence of inflammatory polyarthritis on cancer incidence and survival

Patients with rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease, have a high risk of death from disease - at least double the risk of the general population, studies overwhelmingly show. Evidence has been less clear on whether RA patients are exceptionally vulnerable to dying from cancer.

27 Feb 2007